DNA Synthesis in Multiple Myeloma Cells following Cell Cycle-nonSpecific Chemotherapy

David S. Alberts, David W. Golde

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

During intermittent alkylating drug therapy the in vitro myeloma cell thymidine-3 H-labeling index increases progressively after each treatment course to values as high as 45%. Elevated tumor cell-labeling indices are observed in both responding and nonresponding myeloma patients after cell cycle-nonSpecific therapy. In order to determine the mechanism underlying the increased labeling index in treated myeloma patients, we performed autoradiographic studies in which bone marrow cells were incubated with cytosine arabinoside (105 M) or hydroxyurea (103M) before exposure to thymidine-3 H. In all five patients studied, incubation of the myeloma cells with either of the S-phase-Specific agents resulted in marked inhibition of thymidine-3H uptake. These observations indicate that scheduled (prereplicative) and not repair DNA synthesis is the basic mechanism underlying the high labeling indices. The concentrations of cytosine arabinoside and hydroxyurea, which block DNA synthesis by myeloma cells in vitro, are in the range attainable in vivo. Cell cycle-Specific antitumor agents could potentially be effective in myeloma patients when the tumor cell-labeling index is elevated after cell cycle-nonSpecific therapy.

Original languageEnglish (US)
Pages (from-to)2911-2914
Number of pages4
JournalCancer Research
Volume34
Issue number11
StatePublished - Nov 1974
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'DNA Synthesis in Multiple Myeloma Cells following Cell Cycle-nonSpecific Chemotherapy'. Together they form a unique fingerprint.

  • Cite this